Bastian Ramms

Bastian Ramms

Auto-generated profile, based on publicly available information

Bastian Ramms

Division of Endocrinology and Metabolism, Department of Medicine (B.R., C.C., P.L.S.M.G.), University of California San Diego, La Jolla

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
ATAnnakaisa Tirronen
Annakaisa Tirronen
TVTaina Vuorio
Taina Vuorio
SKSanna Kettunen
Sanna Kettunen
KHKrista Hokkanen
Krista Hokkanen
BRBastian Ramms
Bastian Ramms
Seppo Ylä-HerttualaSeppo Ylä-Herttuala
Seppo Ylä-Herttuala
Objective—: Dyslipidemia is one of the key factors behind coronary heart disease. Blood and lymphatic vessels play pivotal roles in both lipoprotein metabolism and development of atherosclerotic plaques. Recent studies have linked members of VEGF (vascular endothelial growth factor) family to lipid metabolism, but the function of VEGF-D has remained unexplored. Here, we investigated how the deletion of VEGF-D affects lipid and lipoprotein metabolism in atherogenic LDLR −/− ApoB 100/100 mice. Approach and Results—: Deletion of VEGF-D (VEGF-D −/− LDLR −/− ApoB 100/100 ) led to markedly elevated plasma cholesterol and triglyceride levels without an increase in atherogenesis. Size distribution and hepatic lipid uptake studies confirmed a delayed clearance of large chylomicron remnant particles that cannot easily penetrate through the vascular endothelium. Mechanistically, the inhibition of VEGF-D signaling significantly decreased the hepatic expression of SDC1 (syndecan 1), which is one of the main receptors for chylomicron remnant uptake when LDLR is absent. Immunohistochemical staining confirmed reduced expression of SDC1 in the sinusoidal surface of hepatocytes in VEGF-D deficient mice. Furthermore, hepatic RNA-sequencing revealed that VEGF-D is also an important regulator of genes related to lipid metabolism and inflammation. The lack of VEGF-D signaling via VEGFR3 (VEGF receptor 3) led to lowered expression of genes regulating triglyceride and cholesterol production, as well as downregulation of peroxisomal β-oxidation pathway. Conclusions—: These results demonstrate that VEGF-D, a powerful lymphangiogenic and angiogenic growth factor, is also a major regulator of chylomicron metabolism in mice.

1 September 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
SPSilvia Cecilia Pacheco-Velázquez
Silvia Cecilia Pacheco-Velázquez
COCarlota Oleaga
Carlota Oleaga
BRBastian Ramms
Bastian Ramms
JHJoshua Hay
Joshua Hay
PMPaul A. Mueller
Paul A. Mueller
NPNathalie Pamir
Nathalie Pamir
BACKGROUND: Hepatic heparan sulfate proteoglycans (HSPGs) accelerate the clearance of PCSK9 (proprotein convertase subtilisin/kexin type 9). We tested the hypothesis that free- and LDL (low-density lipoprotein)–bound PCSK9 forms have different HSPG-mediated clearance kinetics. METHODS: Metabolic and turnover studies were performed after administration of free- and LDL-bound PCSK9 to 2 HSPG knockout mouse models: (1) Global knockout of syndecan-1 ( Sdc1 −/ − ), an HSPG involved in hepatic triglyceride clearance; and (2) hepatocyte-specific knockout of heparan sulfate N-deacetylase/N-sulfotransferase (AlbCre + Ndst1 f/f ). RESULTS: The clearance of both free- and LDL-bound PCSK9 followed a 2-phase decay behavior comprising a fast and a slow phase. The more notorious effect of HSPG deletion was on the slow phase: the clearance of free-PCSK9 was faster in Sdc1 −/ − mice (t 1/2,slow [half-life on the slow phase] 13.5±1.5 minutes; P =0.0305) than in wild-type (t 1/2,slow 28.8±4.2 minutes) and AlbCre + Ndst1 f/f mice (t 1/2,slow 32.7±4.9 minutes). The clearance of LDL-bound PCSK9 was slower yet not statistically significant in Sdc1 −/ − mice (t 1/2,slow 111.2±21.6 minutes) than in wild-type (t 1/2,slow 52±6.4 minutes) and AlbCre + Ndst1 f/f mice (t 1/2,slow 39.55±2.96 minutes). However, the area under the curve showed a delayed clearance of LDL-bound PCSK9 in Sdc1 −/ − mice (44 576±2435 min×ng, P =0.004) but not in AlbCre + Ndst1 f/f (34 738±3721 min×ng, P =0.578) mice compared with wild-type (30 865±1907 min×ng). Hepatic Ndst1 -deficiency did not alter hepatic PCSK9 or LDLR (LDL receptor) expression. CONCLUSIONS: The clearance rate of plasma LDL-bound PCSK9 is slower than the clearance rate of its free form. The HSPG syndecan-1 modestly contributes to PCSK9 clearance through an LDLR-independent pathway.